morgans - eps 74.5c/share by fy2016!, page-14

Thanks yogistone and Tachyon_Nova. What I am concern is that Moxduo did not pass FDA at first time, because it didn't show clear advantage against Morphine or Oxycodone based on the data provided(study 008). So it asked for more information(Study 022). But can Study 022 convince FDA to accept Moxduo? It should be cautious to suggest Moxduo have better chance to pass FDA this time. It seems, based on Study 022, Moxduo IR only show better result of oxygen desaturation against 16mg oxycodone and not 24mg morphine.
REfer: http://www.biotechdaily.com.au/media/backissues/2013/02%20Feb/BD%20Biotech%20Daily%20Feb%2028.pdf